Skip to main content
. 2021 Sep 20;12:5423. doi: 10.1038/s41467-021-25430-9

Fig. 7. Prognostic significance of clinical parameters and molecularly defined subtypes.

Fig. 7

a, b Samples were stratified according to the clinical parameters a and molecular-defined subtypes b. a Age, age at diagnosis; PRETEXT, the PRETEXT staging system; Annotation factors (M distant metastasis, + positive for VPERFNH, − negative for the annotation factors); Histology histologic subtypes. b Expression, gene expression; CIN, chromosomal instability; Enhancer, enhancer methylation; Promoter, promoter methylation. Statistical significance was analyzed using the log-rank test. c Surrogate methylation marker DLX6-AS1 (cg22421859, chr7:96622043) for all childhood hepatoblastoma (HB) cases (left) and limited subgroup (middle, for infant HB; right, for AF-positive cases). d Volcano plots of differential methylation between older HB cases (P1, P2) and younger cases (P3, P4). The heat map in the bottom shows the methylation status of the 10 most significant CpG sites using the two-sided Fisher’s exact test. e Surrogate methylation, DLX6-AS1 to distinguish methylation subtypes. Statistical significance was analyzed using Fisher’s exact test. f Sankey diagram stratifying the HB cases with poor prognosis by DLX6-AS1 methylation.